The April 2026 removal from Category 2 enforcement acknowledges this and reflects a more scientifically accurate treatment of GHK-Cu
The second round awardees for this program will be announced soon
Last reviewed: June 22, 2026 Last updated: June 22, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
While there are clinical and preclinical studies which suggest additive or synergistic benefit in fertility protocols, the evidence remains quite limited
1 for more details)
The formulator or manufacturer is solely responsible for the safety assessment, stability testing, preservation, compatibility, labeling, and regulatory compliance of any finished cosmetic product made with Copper Tripeptide-1 (GHK-Cu)